Aurélie Barrail-Tran

Aurélie Barrail-Tran

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 January 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
Caroline PassaesCaroline Passaes
Caroline Passaes
DDDelphine Desjardins
Delphine Desjardins
ACAnaïs Chapel
Anaïs Chapel
VMValérie Monceaux
Valérie Monceaux
JLJulien Lemaitre
Julien Lemaitre
ASAsier Sáez-Cirión
Asier Sáez-Cirión
HIV remission can be achieved in some people, called post-treatment HIV controllers, after antiretroviral treatment discontinuation. Treatment initiation close to the time of infection was suggested to favor post-treatment control, but the circumstances and mechanisms leading to this outcome remain unclear. Here we evaluate the impact of early (week 4) vs. late (week 24 post-infection) treatment initiation in SIVmac251-infected male cynomolgus macaques receiving 2 years of therapy before analytical treatment interruption. We show that early treatment strongly promotes post-treatment control, which is not related to a lower frequency of infected cells at treatment interruption. Rather, early treatment favors the development of long-term memory CD8+ T cells with enhanced proliferative and SIV suppressive capacity that are able to mediate a robust secondary-like response upon viral rebound. Our model allows us to formally demonstrate a link between treatment initiation during primary infection and the promotion of post-treatment control and provides results that may guide the development of new immunotherapies for HIV remission.

1 March 2020 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
HGHélène Gouget
Hélène Gouget
GNGaelle Noé
Gaelle Noé
ABAurélie Barrail-Tran
Aurélie Barrail-Tran
VFValérie Furlan
Valérie Furlan

1 June 2019 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
TGThibaut Gelé
Thibaut Gelé
VFValérie Furlan
Valérie Furlan
ATAnne-Marie Taburet
Anne-Marie Taburet
CPCoralie Pallier
Coralie Pallier
PBPierre-Hadrien Becker
Pierre-Hadrien Becker
ACAntoine Chéret
Antoine Chéret
This study aimed to determine dolutegravir cerebrospinal fluid (CSF) diffusion in 13 patients with HIV-related cerebral impairment enrolled in a real-life observational study. Dolutegravir median (range) CSF concentration [9.6 (3.6–22.8) ng/mL] reached CSF therapeutic concentrations whatever the blood-brain barrier status and diffused in correlation with the albumin quotient (P = .0186).

12 January 2022 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Open access
PDF file
LLLaura Labarthe
Laura Labarthe
TGThibaut Gelé
Thibaut Gelé
HGHélène Gouget
Hélène Gouget
MBMariam-Sarah Benzemrane
Mariam-Sarah Benzemrane
PCPauline Le Calvez
Pauline Le Calvez
ABAurélie Barrail-Tran
Aurélie Barrail-Tran
Background: Studies of antiretroviral drug (ARV) tissue distribution in preclinical models, such as mice, are key to understanding viral persistence. Objectives: To determine the plasma and tissue pharmacokinetics and tissue distributions of tenofovir, emtricitabine and dolutegravir in mice. Methods: ARVs were simultaneously administered to two different strains, and their levels in plasma and tissue samples were determined by a validated LC-MS/MS method. A non-compartmental analysis was performed to estimate the main pharmacokinetic parameters. A tissue penetration factor (TPF) was calculated as the ratio of the concentration in the tissue concerned to that in plasma. Results: ARV plasma pharmacokinetic parameters in both strains were similar to those estimated in the clinical context. Tissue concentrations were highest in the digestive tract, followed by the liver and kidneys, lymphatic system, pancreas, adipose tissue and lungs. Tissue concentrations were lowest in the brain. Triple therapy could not be considered effective in any of the tissues considered. The TPF values obtained showed that tenofovir diffused widely, especially in the digestive tract, liver and kidneys. Emtricitabine had a TPF above 100% in two-thirds of the tissues. Dolutegravir was poorly distributed to all tissues. Conclusions: Drug specificity was observed, with higher levels of exposure to tenofovir than to emtricitabine or dolutegravir. Tissue specificity was also observed, with strong penetration of the digestive tract and weak penetration of the brain. These data have important implications for future preclinical and clinical studies for developing new HIV therapies with the goal of an HIV cure.

20 October 2020 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Closed access
PDF file
TGThibaut Gelé
Thibaut Gelé
HGHélène Gouget
Hélène Gouget
VFValérie Furlan
Valérie Furlan
PBPierre-Hadrien Becker
Pierre-Hadrien Becker
ATAnne-Marie Taburet
Anne-Marie Taburet
ABAurélie Barrail-Tran
Aurélie Barrail-Tran
This study aimed to characterize in vitro dolutegravir (DTG) and bictegravir (BIC) binding. They had a preferential binding to human serum albumin (HSA) with two classes of albumin sites. Human alpha-1-acid glycoprotein (HAAG) binding of DTG and BIC showed an atypical nonlinear binding. The low-affinity site on HSA, the main plasma binding protein, suggests that the high protein binding rate should not impair passive diffusion.

11 September 2021 in Journal of Antimicrobial Chemotherapy
Verified
Journal Article
Closed access
PDF file
TGThibaut Gelé
Thibaut Gelé
ACAntoine Chéret
Antoine Chéret
AGAlicia Castro Gordon
Alicia Castro Gordon
LNLionelle Nkam
Lionelle Nkam
VFValérie Furlan
Valérie Furlan
ABAurélie Barrail-Tran
Aurélie Barrail-Tran
The penetration of antiretroviral drugs into deep compartments, such as the CNS, is a crucial component of strategies towards an HIV cure. This study aimed to determine CSF concentrations of bictegravir, emtricitabine and tenofovir in patients with HIV-related CNS impairment (HCI) enrolled in a real-life observational study. Patients with HCI treated by optimized ART, including bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) for at least 1 month were enrolled. Plasma and CSF concentrations were measured by quality control-validated assays (LC-MS/MS). The inhibitory quotient (IQARV) was calculated as the ratio of unbound (bictegravir) or total (emtricitabine and tenofovir) concentration to half (or 90%) maximal inhibitory concentration for bictegravir (or emtricitabine and tenofovir). All numerical variables are expressed as median (range). Twenty-four patients (nine women) were enrolled. The age was 45 (26–68) years. Unbound bictegravir and total emtricitabine and tenofovir CSF concentrations were 4.4 (1.6–9.6), 84.4 (28.6–337.4) and 1.6 (0.7–4.3) ng/mL, respectively. The unbound bictegravir CSF fraction was 34% (15%–82%) versus 0.33% (0.11%–0.92%) in plasma. Three patients had an IQARV above unity for the three antiretrovirals. Factors positively associated with the CSF concentration (unbound for bictegravir) were age and total plasma concentration for the three antiretrovirals. Patients aged over 51 years had higher CSF concentrations (unbound for bictegravir). We observed low CSF exposure to bictegravir, emtricitabine and tenofovir. These results suggest that BIC/FTC/TAF should be used with caution as first-line treatment for people living with HIV with HCI under 51 years of age.